Showing 3051-3060 of 3223 results for "".
- Zeiss Launches First Dual-Speed Swept-Source OCT/OCTA at ARVOhttps://modernod.com/news/zeiss-launches-first-dual-speed-swept-source-oct-octa-at-arvo/2476503/Zeiss launched the PLEX Elite 2.0, the first dual-speed swept-source OCT/OCTA that will scan at 200kHz, in addition to 100kHz, providing doctors a more detailed view into the retina. Varying speeds can be applied to different disease states in the eye and expand re
- Aerie Pharmaceuticals Announces Acceptance of Its IND Application for Sustained-Release Implant for Retinal Diseaseshttps://modernod.com/news/aerie-pharmaceuticals-announces-acceptance-of-its-ind-application-for-sustained-release-implant-for-retinal-diseases/2476498/Aerie Pharmaceuticals announced that the FDA has reviewed the investigational new drug (IND) application for AR-13503, a novel multi-kinase (Rho kinase/Protein kinase C (ROCK/PKC)) inhibitor sustained-release implant, and it is now in effect, allowing Aerie to initiate human studies in the treat
- NovaBay Pharmaceuticals Announces New Partner Pharmacy Programhttps://modernod.com/news/novabay-pharmaceuticals-announces-new-partner-pharmacy-program/2476465/NovaBay Pharmaceuticals announced a new pharmacy partnering program in an effort to ensure all patients in the United States have reliable and affordable access to prescription Avenova, according to a company news release. NovaBay has recently added six new pharmacies as Avenova channel partners.
- Data Published on Acthar Gel Disease Status and Utilization Patterns in Uveitis Patientshttps://modernod.com/news/data-published-on-acthar-gel-disease-status-and-utilization-patterns-in-uveitis-patients/2476455/Mallinckrodt announced data from a retrospective chart review that analyzed physician assessments of 91 U.S. patients diagnosed with uveitis who had been treated with Acthar Gel (repository corticotropin injection) in the previous 12 months. All patients had completed
- PECAA Community Raises $116,000 for Optometry Giving Sighthttps://modernod.com/news/pecaa-community-raises-116000-for-optometry-giving-sight/2476452/PECAA, a nationwide doctor alliance group for independent eye care professionals, announced in March that through its Growing Through Giving Program, $116,000 had been raised in 2018 for the organization’s charity of
- IStent Inject Device Lowers IOP After Cataract Surgery in Glaucoma Patientshttps://modernod.com/news/istent-inject-device-lowers-iop-after-cataract-surgery-in-glaucoma-patients/2476438/In patients with mild to moderate glaucoma and cataract, the second-generation iStent inject system, with two redesigned stents, reduces IOP more than cataract surgery alone, according to results of a new pivotal trial, as reported by Reut
- Oxurion NV Announces Full Enrollment of Its Phase 2 Trial Evaluating Combination of Anti-PlGF (THR-317) and Anti-VEGF (Ranibizumab) for the Treatment of DMEhttps://modernod.com/news/oxurion-nv-announces-full-enrollment-of-its-phase-2-trial-evaluating-combination-of-anti-plgf-thr-317-and-anti-vegf-ranibizumab-for-the-treatment-of-dme/2476439/Oxurion NV announced that all patients have been enrolled in its phase 2 trial evaluating its THR-317, a humanized antibody against placental growth factor (PlGF), in combination with anti-VEGF (ranibizumab), an anti-vascular endothelial growth factor (VEGF) antibody, for the treatment of diabeti
- I-PEN Osmolarity System Now Available in Brazil Through Partnership with DryComhttps://modernod.com/news/i-pen-osmolarity-system-now-available-in-brazil-through-partnership-with-drycom/2476420/The I-PEN is the world’s first, point-of-care, electronic diagnostic testing device to detect and indirectly measure the tear film osmolarity levels associated with marginal, mild, moderate and severe dry eye disease. The I-PEN Osmolarity System, used in conjunction with the I-PEN Osmolarity Sing
- Study: Excess Hormones Could Cause a Condition That Can Lead to Blindness in Womenhttps://modernod.com/news/study-excess-hormones-could-cause-a-condition-that-can-lead-to-blindness-in-women/2476403/Research led by the University of Birmingham, UK, has found that increased levels of hormones including testosterone could cause a brain condition that can lead to blindness in women. Idiopathic Intracranial Hypertension—also known as IIH—is caused by high pressure in the brain with conseq
- Compulink Previews New User Interface for its Optometry SMART EHR at Vision Expo Easthttps://modernod.com/news/compulink-previews-new-user-interface-for-its-optometry-smart-ehr-at-vision-expo-east/2476404/Compulink Healthcare Solutions, the creator of Advantage SMART Practice, an all-in-one EHR and practice management solution powered by artificial intelligence (AI), previewed the new user interface for its Eyecare Advantage at Vision Expo this week. Designed by a team of usability experts,